All content for Retinal Physician Insider is the property of Retinal Physician Insider and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Peter Kaiser, MD and Judy Kim, MD discuss DRCR and key findings from recent protocols.
Peter Kaiser, MD, and Rishi Singh, MD assess treatment goal challenges with persistent fluid, accompanied with inability to extend injection intervals.
Peter Kaiser, MD, and Michael Singer, MD, discuss strategies choosing an anti-VEGF treatment based on patients’ personal needs, how to handle non-responders, and what do to when inflammation is a concern.
Peter Kaiser, MD, and Timothy Murray, MD, MBA, discuss the HAWK and HARRIER phase 3 studies evaluating the safety and efficacy of brolucizumab for wet AMD.
Peter Kaiser, MD, and Jeffrey Heier, MD, examine the findings of the Novartis-appointed Safety Review Committee’s independent assessment of post-marketing cases of inflammation following the approval of brolucizumab.
